CRISPR in Drug Discovery 2019: From Targets to Therapeutics

King's Centre, Oxford
27 - 28 February 2019

ELRIG

Conference Directors:
Barry Rosen (AstraZeneca), **Lisa Mohamet** (GlaxoSmithKline) &
Dan Ebner (Target Discovery Institute University of Oxford)

Genome Engineering, including Zinc-finger, TALEN and most recently CRISPR/Cas9, has become a powerful tool in the drug discovery pipeline. The inaugural CRISPR in Drug Discovery: From Targets to Therapeutics meeting will focus on the application of genome engineering to identify novel drug targets through large scale CRISPR based functional genomics studies, target validation in developing advanced cellular and in vivo disease models, and the pioneering applications in therapeutic genome editing.

Join scientists from academia, pharma, biotech, and CRO's to hear talks given by speakers at the cutting edge of genome engineering. Take part in commercial vendor lab-based workshops, network at the exhibition and innovation forum and gain strategic insights into solutions for increasing the success of drug discovery and development.

The scientific program for this CRISPR in Drug Discovery 2019 meeting will include:

- Large-scale CRISPR functional genomics studies for drug target identification and validation
- Application of genome engineering in developing biological models of disease from single cell through to complex in vitro tissue systems and in vivo models
- Cutting edge CRISPR genome engineering technologies and their emerging applications
- A perspective from technology leaders toward the future therapeutic applications of genome engineering

Call for Posters

Submission deadlines:
Poster Spotlights: **7 February 2019**
General posters: **20 February 2019**

Sponsorship & Exhibition

For sponsorship & exhibition enquiries, contact Sanj Kumar:
sanj.kumar@elrig.org

www.elrig.org